Chastity McCullick
Family · Bolivar, MONPI 1477838571
Payments from drug & device makers
Across 75 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$393
- Novo Nordisk$216
- Otsuka America Pharmaceutical, Inc.$147
- AstraZeneca$112
- Novartis$74
- Avanir Pharmaceuticals, Inc.$50
- plus $377 from 13 others
What the payments were for
- Food & beverage$1,368100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $393 |
| Novo Nordisk | 11 | $216 |
| Otsuka America Pharmaceutical, Inc. | 7 | $147 |
| AstraZeneca | 6 | $112 |
| Novartis | 4 | $74 |
| Avanir Pharmaceuticals, Inc. | 3 | $50 |
| Lilly USA, LLC | 3 | $48 |
| Abbott | 2 | $45 |
| Astellas Pharma US Inc | 2 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Dexcom, Inc. | 2 | $31 |
| Amgen | 2 | $29 |
| Indivior Inc. | 2 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Merck | 1 | $19 |
| Optinose US, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$1,368 in reported general payments places this provider in the 70th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 47 | $46,421 |
| MounjaroTirzepatide | 30 | $42,195 |
| RybelsusSemaglutide | 24 | $38,910 |
| OzempicSemaglutide | 37 | $35,542 |
| EliquisApixaban | 34 | $24,328 |
| FarxigaDapagliflozin Propanediol | 39 | $23,230 |
| LinzessLinaclotide | 23 | $18,012 |
| MyrbetriqMirabegron | 24 | $12,077 |
| JardianceEmpagliflozin | 15 | $10,407 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $9,202 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,370 |
| JanuviaSitagliptin Phosphate | 11 | $6,451 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $5,502 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $4,368 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 128 | $4,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $48 | $88,61577 claims |
| Novo NordiskRybelsus, Ozempic | $216 | $74,45261 claims |
| AstraZenecaFarxiga | $112 | $23,23039 claims |
| AbbVieLinzess | $393 | $18,01223 claims |
| Astellas Pharma US IncMyrbetriq | $43 | $12,07724 claims |
| MerckJanuvia | $19 | $6,45111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,812 family providers in Missouri.
Other family in Bolivar
- Bailey ShunyakovBolivar$27K
- Bethany MartinBolivar$17K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.